The purpose of this study is to further evaluate an experimental drug called linerixibat in patients with primary biliary cholangitis (PBC). Linerixibat (also referred to as GSK2330672) works in the digestive system by stopping the buildup of bile by blocking it from reentering the blood and causing it to be removed in stools instead. Researchers aim to determine the effects of linerixibat on PBC patients when given for a longer period of time. Participants in this study have itching (in parts or all of the body) caused by PBC and have also taken part in the GLISTEN study; information from the GLISTEN study will be used in this study for analysis. Participants will take linerixibat in addition to their current itch and PBC treatment. They will also be asked to visit the clinic to complete questionnaires and other routine procedures.
Long-term Safety and Tolerability Study of Linerixibat for the Treatment of Cholestatic Pruritus in Participants with Primary Biliary Cholangitis